Results 31 to 40 of about 34,135 (204)

GBM radiosensitizers: dead in the water…or just the beginning? [PDF]

, 2017
The finding that most GBMs recur either near or within the primary site after radiotherapy has fueled great interest in the development of radiosensitizers to enhance local control.
Bindra, Ranjit S., Chalmers, Anthony J., Dewhirst, Mark, Evans, Sydney   +3 more
core   +1 more source

A Quaternary Solid Dispersion System for Improving the Solubility of Olaparib

Solids
To improve the low solubility of poorly water soluble olaparib, in the following study, we prepared olaparib-loaded quaternary solid dispersions with hypromellose, Tween 20 or Labrasol, and colloidal silica.
Tae-Han Yun, Jeong-Gyun Lee, Kyu-Ho Bang, Jung-Hyun Cho, Kyeong-Soo Kim   +4 more
doaj   +1 more source

MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC

Journal of Hematology & Oncology, 2020
Background PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are acceptably used in assessment of Olaparib ...
Chenggong Sun, Wenyu Cao, Chunping Qiu, Chengcheng Li, Samina Dongol, Zhiwei Zhang, Ruifen Dong, Kun Song, Xingsheng Yang, Qing Zhang, Beihua Kong   +10 more
doaj   +1 more source

Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma

EJNMMI Research, 2022
Purpose Radiopharmaceuticals targeting poly(ADP-ribose) polymerase (PARP) have emerged as promising agents for cancer diagnosis and therapy. PARP enzymes are expressed in both cancerous and normal tissue.
Chung Ying Chan, Samantha L. Hopkins, Florian Guibbal, Anna Pacelli, Julia Baguña Torres, Michael Mosley, Doreen Lau, Patrick Isenegger, Zijun Chen, Thomas C. Wilson, Gemma Dias, Rebekka Hueting, Véronique Gouverneur, Bart Cornelissen   +13 more
doaj   +1 more source

Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice

Journal of Biomedical Science, 2022
Background Seaweed polysaccharides have been recommended as anticancer supplements and for boosting human health; however, their benefits in the treatment of triple-negative breast cancers (TNBCs) and improving immune surveillance remain unclear ...
Li-Mei Chen, Pao-Pao Yang, Aushia Tanzih Al Haq, Pai-An Hwang, You-Chen Lai, Yueh-Shan Weng, Michelle Audrey Chen, Hsin-Ling Hsu   +7 more
doaj   +1 more source

Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterization [PDF]

, 2017
Purpose: Maintenance therapy with olaparib has improved progression-free survival in women with high-grade serous ovarian cancer (HGSOC), particularly those harboring BRCA1/2 mutations.
Barrett, J. Carl, Bowtell, David D.l., Burnier, Julia V, Dougherty, Brian A, Gilks, Blake, Gourley, Charlie, Ho, Tony W, Hodgson, Darren, Karakasis, Katherine, Kaye, Stanley B., Kohn, Elise C, Lai, Zhongwu, Lanchbury, Jerry S, Ledermann, Jonathan, Lheureux, Stephanie, Matulonis, Ursula A, O'connor, Mark J, Oza, Amit M, Panzarella, Tony, Robertson, Jane D, Runswick, Sarah, Scott, Clare L, Timms, Kirsten M   +22 more
core   +2 more sources

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2 [PDF]

, 2017
Objective: An integrated analysis was undertaken to characterize the antitumor activity and safety profile of the oral poly(ADP-ribose) polymerase inhibitor rucaparib in patients with relapsed high-grade ovarian carcinoma (HGOC). Methods: Eligible
Bell-McGuinn, Katherine, Brenton, James D., Castro, Cesar M., Chen, Lee-may, Coleman, Robert L., Giordano, Heidi, Goble, Sandra, Konecny, Gottfried E., Kristeleit, Rebecca S., Leary, Alexandra, Lin, Kevin K., Ma, Ling, Maloney, Lara, Mcneish, Iain A., Oaknin, Ana, Oza, Amit M., O’Malley, David M., Provencher, Diane, Raponi, Mitch, Ray-Coquard, Isabelle, Rolfe, Lindsey, Shapira-Frommer, Ronnie, Sun, James, Swisher, Elizabeth M., Tinker, Anna V.   +24 more
core   +1 more source

Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy

Translational Oncology, 2021
P-glycoprotein (P-gp) is an adenosine triphosphate (ATP)-dependent drug efflux protein commonly associated with multidrug resistance in cancer chemotherapy.
Yan Baglo, Aaron J. Sorrin, Xiaocong Pu, Cindy Liu, Jocelyn Reader, Dana M. Roque, Huang-Chiao Huang   +6 more
doaj   +1 more source

Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells [PDF]

, 2016
PURPOSE: Despite recent advances in the treatment of metastatic prostate cancer, survival rates are low and treatment options are limited to chemotherapy and hormonal therapy.
Mairs, Robert J., Rae, Colin
core   +2 more sources

IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer

iScience
Summary: Olaparib is a pioneering PARP inhibitor (PARPi) approved for treating castration-resistant prostate cancer (CRPC) tumors harboring DNA repair defects, but clinical resistance has been documented.
Amy R. Leslie, Shu Ning, Cameron M. Armstrong, Leandro S. D’Abronzo, Masuda Sharifi, Zachary A. Schaaf, Wei Lou, Chengfei Liu, Christopher P. Evans, Alan P. Lombard, Allen C. Gao   +10 more
doaj   +1 more source